Atai Life Sciences N.V.

Atai Life Sciences N.V.

ATAI
Atai Life Sciences N.V.US flagNASDAQ Global Market
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Dr. Srinivas G. Rao M.D., Ph.D.
Full Time Employees
83
Sector
Healthcare
Industry
Biotechnology
Address
Krausenstrasse 9-10 Berlin Germany 10117
IPO Date
Jun 18, 2021
Website
atai.life
Business
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Company News

  • atai Life Sciences announces pricing of $55M public offering of shares

  • atai Life Sciences Announces Pricing of Public Offering of Common Shares

  • atai Life Sciences unveils $55M public offering to advance mental health treatments

  • atai Life Sciences Announces Proposed Public Offering of Common Shares

  • atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trial - ICYMI

  • atai Life Sciences-backed psychedelic drug could offer superior value, analysts believe

  • atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout

  • Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

  • atai Life Sciences poised for near-term value creation with release of psychedelics trial data: analysts

  • atai Life Sciences unveils positive results from Beckley Psytech's alcohol use disorder trial

  • Spravato sales surged highlights commercial viability of psychedelics, analysts believe

  • atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline

  • atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

  • atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts

  • atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01

  • RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say

  • IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

  • atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

  • Psychedelic Stock Deep Dive: Atai Life Sciences

  • atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI